Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Immortal time bias in observational studies of drug effects.

Suissa S.

Pharmacoepidemiol Drug Saf. 2007 Mar;16(3):241-9.

PMID:
17252614
2.
3.

Immeasurable time bias in observational studies of drug effects on mortality.

Suissa S.

Am J Epidemiol. 2008 Aug 1;168(3):329-35. doi: 10.1093/aje/kwn135. Epub 2008 May 30.

4.

Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease.

Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB.

Ann Intern Med. 2008 Sep 16;149(6):380-90.

PMID:
18794557
5.

Bias in observational study of the effectiveness of nasal corticosteroids in asthma.

Suissa S, Ernst P.

J Allergy Clin Immunol. 2005 Apr;115(4):714-9.

PMID:
15805989
6.

Immortal time bias in pharmaco-epidemiology.

Suissa S.

Am J Epidemiol. 2008 Feb 15;167(4):492-9. Epub 2007 Dec 3. Review.

7.
8.

Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias.

Kiri VA, Pride NB, Soriano JB, Vestbo J.

Am J Respir Crit Care Med. 2005 Aug 15;172(4):460-4. Epub 2005 May 18.

PMID:
15901610
9.

Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.

Sobieraj DM, White CM, Coleman CI.

Clin Ther. 2008 Aug;30(8):1416-25. doi: 10.1016/j.clinthera.2008.08.004.

PMID:
18803985
10.

Inhaled glucocorticoids in COPD: immortal time bias.

Pride NB, Vestbo J, Soriano JB, Kiri VA.

Am J Respir Crit Care Med. 2003 Jul 1;168(1):127. No abstract available.

PMID:
12870509
11.

Co-morbidity in COPD: the effects of cardiovascular drug therapies.

Suissa S.

Respiration. 2010;80(1):3-7. doi: 10.1159/000315387. Epub 2010 Jun 14. Review.

PMID:
20551712
12.

Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching.

Akazawa M, Biddle AK, Stearns SC.

Clin Ther. 2008;30 Spec No:1003-16. doi: 10.1016/j.clinthera.2008.05.020.

PMID:
18640475
13.

Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease.

Lee TA, Wilke C, Joo M, Stroupe KT, Krishnan JA, Schumock GT, Pickard AS.

Arch Intern Med. 2009 Aug 10;169(15):1403-10. doi: 10.1001/archinternmed.2009.233. Erratum in: Arch Intern Med. 2009 Sep 28;169(17):1568.

PMID:
19667304
14.

[Do inhaled corticosteroids reduce mortality in chronic obstructive pulmonary disease?].

Bridevaux PO, Leuenberger P.

Rev Med Suisse. 2005 Nov 16;1(41):2673-4, 2677-9. Review. French.

PMID:
16355882
15.

Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis.

Puhan MA, Bachmann LM, Kleijnen J, Ter Riet G, Kessels AG.

BMC Med. 2009 Jan 14;7:2. doi: 10.1186/1741-7015-7-2.

16.

Enhanced persistence with tiotropium compared with other respiratory drugs in COPD.

Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JW, Herings RM.

Respir Med. 2007 Jul;101(7):1398-405. Epub 2007 Mar 23.

17.
18.

Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease.

Ekström MP, Hermansson AB, Ström KE.

Am J Respir Crit Care Med. 2013 Apr 1;187(7):715-20. doi: 10.1164/rccm.201208-1565OC.

PMID:
23328521
19.

Survival with tiotropium compared to long-acting Beta-2-agonists in Chronic Obstructive Pulmonary Disease.

Gershon AS, Wang L, To T, Luo J, Upshur RE.

COPD. 2008 Aug;5(4):229-34. doi: 10.1080/15412550802237507.

PMID:
18671148
20.

Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease.

Lee TA, Schumock GT, Bartle B, Pickard AS.

Pharmacotherapy. 2009 Sep;29(9):1039-53. doi: 10.1592/phco.29.9.1039.

PMID:
19698009
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk